FeesSafety
Pluang+

GRAIL nears FDA approval for Galleri cancer test, boosting market potential and scaling costs.

Company Fundamentals
19 Nov 2026, 12:53 WIB
The Motley Fool Team
View Source
Bullish
GRAIL nears FDA approval for Galleri cancer test, boosting market potential and scaling costs.

GRAIL reported strong growth in its Galleri multi-cancer early detection test, completing over 174,000 tests in nine months of 2026 and seeing a 24% volume increase in Q3. A positive FDA advisory vote positions Galleri to become the first FDA-approved multi-cancer screening tool, with a final decision expected early 2027. The company is prioritizing market expansion over short-term margins by offering promotional pricing and aims for 50-60% gross margins as scale reduces costs. GRAIL holds $788.7 million in cash, supporting its growth and insurance coverage efforts through 2029.

GRAIL's recent developments provide context for readers interested in health-sector stocks. As of Nov 19, 2026, 69 of 150 health-sector US stocks on Pluang rose while 76 fell. Notable movers include ALMS at USD 4.39 down 9.30%, BFLY at USD 6.26 up 8.87%, and SYRE at USD 101.60 up 8.30%, with typical hold times ranging from 6 to 23 days.

More News

Anthropic IPO set at $1.5T valuation, raising $107B amid record growth and huge AI market potential.

Anthropic IPO set at $1.5T valuation, raising $107B amid record growth and huge AI market potential.

Anthropic, an AI startup founded five years ago, is going public with a $1.5 trillion valuation, raising $107.3 billion in its IPO. The company has shown unprecedented growth, with revenue up over 1,100% year-over-year and a run rate of $68 billion b...

Market News
Bullish
46 minutes ago
GTA VI breaks pre-order records, boosting Take-Two stock and revenue outlook.

GTA VI breaks pre-order records, boosting Take-Two stock and revenue outlook.

Grand Theft Auto VI has set a new record with 17.1 million pre-orders, generating $1.65 billion in net revenue before its release on Nov. 19. This surge is expected to significantly boost Take-Two Interactive's fiscal 2027 revenue guidance to around ...

Market News
Bullish
1 hour ago
Magnite outpaces The Trade Desk in 2026 revenue growth amid rising competition in digital ad tech.

Magnite outpaces The Trade Desk in 2026 revenue growth amid rising competition in digital ad tech.

Magnite and The Trade Desk are key players in digital advertising, serving supply-side and demand-side markets respectively. In 2026, Magnite showed accelerating revenue growth, benefiting from streaming companies monetizing content, while The Trade ...

Analyst Insights
Neutral
1 hour ago
Noitom Robotics tops Asia's list of 2026's most promising startups with $5B+ valuation and $10M+ revenue.

Noitom Robotics tops Asia's list of 2026's most promising startups with $5B+ valuation and $10M+ revenue.

Noitom Robotics was ranked the number one startup in Asia on The Information's 2026 list of the 50 most promising global startups. The company, valued at over $5 billion with annual revenue exceeding $10 million, specializes in producing high-quality...

Market News
Bullish
1 hour ago
Noitom Robotics tops Asia's 2026 most promising startups with $500M+ valuation and $10M+ revenue

Noitom Robotics tops Asia's 2026 most promising startups with $500M+ valuation and $10M+ revenue

Noitom Robotics was ranked No. 1 in Asia on The Information's 2026 list of the 50 most promising startups, valued above $500 million with over $10 million in revenue. The company specializes in producing human data for Physical AI, supporting nearly ...

Others
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App